LWMI
CPRX

Legacy Wealth Management (Idaho)’s Catalyst Pharmaceutical CPRX Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$991 Sell
40
-64
-62% -$1.52K ﹤0.01% 872
2025
Q4 		$2.43K Buy
104
+86
+478% +$1.92K ﹤0.01% 645
2025
Q3 		$355 Hold
18
– – ﹤0.01% 709
2025
Q2 		$391 Sell
18
-17
-49% -$401 ﹤0.01% 674
2025
Q1 		$849 Hold
35
– – ﹤0.01% 658
2024
Q4 		$802 Buy
35
+17
+94% +$365 ﹤0.01% 616
2024
Q3 		$411 Buy
+18
New +$334 ﹤0.01% 625

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Legacy Wealth Management (Idaho)'s CPRX Position: Q1 2026 in Review

Legacy Wealth Management (Idaho) reduced its Catalyst Pharmaceutical (CPRX) stake by 62% in Q1 2026, selling an estimated $1.52K and leaving 40 shares worth $991. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Legacy Wealth Management (Idaho) first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.43K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Legacy Wealth Management (Idaho) held 40 shares of Catalyst Pharmaceutical worth $991 as of Q1 2026.
  • Legacy Wealth Management (Idaho) sold 64 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.52K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Legacy Wealth Management (Idaho)'s portfolio in Q1 2026, its #872 holding.
  • Legacy Wealth Management (Idaho) first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
  • Legacy Wealth Management (Idaho)'s Catalyst Pharmaceutical position peaked at $2.43K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q1 2026, filed 7 May 2026.